Biocryst Pharmaceuticals reported $81.02M in Current Liabilities for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
DBV Technologies DBVT:US 26.03M 5.37M
Alnylam Pharmaceuticals ALNY:US $ 605.96M 89.75M
Biocryst Pharmaceuticals BCRX:US $ 81.02M 22.7M
Chemocentryx CCXI:US $ 68.81M 5.79M
Chugai Pharma 4519:JP Y 320515M 6907M
Daiichi Sankyo 4568:JP Y 395268M 40073M
Enanta Pharmaceuticals ENTA:US $ 30.74M 7.15M
Gilead Sciences GILD:US $ 8558M 3052M
GlaxoSmithKline GSK:LN 24278M 608M
Glaxosmithkline GSK:US $ 24278M 608M
Intra Cellular Therapies ITCI:US $ 59.07M 5.72M
IONIS PHARMACEUT IONS:US $ 228.45M 12.1M
Karyopharm Therapeutics KPTI:US $ 66.34M 7.38M
Mirati Therapeutics MRTX:US $ 123.57M 20.09M
Neurocrine Biosciences NBIX:US $ 253.5M 7.7M
Novavax NVAX:US $ 2261M 129.31M
Ptc Therapeutics PTCT:US $ 476.78M 32.57M
Regeneron Pharmaceuticals REGN:US $ 3007.6M 924.9M
Sarepta Therapeutics SRPT:US $ 454.96M 2.23M
Ultragenyx Pharmaceutical RARE:US $ 167.23M 14.14M
Vertex Pharmaceuticals VRTX:US $ 2180.2M 38.2M
YTE INCY:US $ 886.16M 31.86M